{"id":"W4220692570","doi":"10.3389/fimmu.2022.852563","title":"Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Allergan; Greenwich Biosciences; Novartis Pharma; EMD Serono; National Research Foundation; Genentech; European Committee for Treatment and Research in Multiple Sclerosis; Universität Basel; CSL Behring; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Bayer; Celgene; Biogen; Bayer HealthCare; European Commission; Sanofi; TG Therapeutics; Pfizer","keywords":"Teriflunomide; Medicine; Ofatumumab; Internal medicine; Post-hoc analysis; Multiple sclerosis; Expanded Disability Status Scale; Oncology; Gastroenterology; Fingolimod; Immunology; Rituximab; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007418703,0.001004816,0.001695141,0.0004378341,0.0003701265,0.001170206,0.0005084276,0.0007583534,0.00144612],"category_scores_gemma":[0.006838001,0.000278128,0.00219238,0.0006793044,0.0003851415,0.0007159276,0.0004947103,0.0009509696,0.0002227209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003544061,"about_ca_system_score_gemma":0.000576161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004052774,"about_ca_topic_score_gemma":0.001081313,"domain_scores_codex":[0.9974056,0.001589162,0.0002752402,0.0003517473,0.0002583025,0.0001199682],"domain_scores_gemma":[0.9944136,0.001887498,0.002433037,0.0004100882,0.0004068507,0.0004490188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5357511,0.001046279,0.3769272,0.00204001,0.02902189,0.0001079624,0.0001642308,0.001201671,0.003805659,0.00007469372,0.001722446,0.04813682],"study_design_scores_gemma":[0.06799854,0.04374726,0.8491933,0.0004547738,0.03119888,0.0004581969,0.0001196832,0.001494728,0.00194694,0.0004132185,0.002880068,0.00009453226],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815466,0.01458815,0.0003096165,0.0002563817,0.00007206318,0.0003563316,0.001709196,0.0000198664,0.001141835],"genre_scores_gemma":[0.9961957,0.001211849,0.0003045185,0.0001641814,0.0001453704,0.000220621,0.001558789,0.000006542808,0.0001924747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007418703,"threshold_uncertainty_score":0.03923434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04300600018264319,"score_gpt":0.2833575377059527,"score_spread":0.2403515375233095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}